Selank

A neuroregulatory peptide examined in relation to anxiety, GABA, enkephalins, and regulation of the stress response

Background

Selank is a synthetic heptapeptide — seven amino acids, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro — built on the scaffold of tuftsin, a naturally occurring peptide related to the immune system. Research attention has centered on anxiety, the stress response, neurotransmission and cognitive function [1-4]. Its literature looks nothing like that of psychiatric drugs that have gone through large global development programs. Human work does exist, including comparative studies in patients with anxiety, but a substantial share of it appeared in Russian, in relatively small samples, and came out of a narrow set of research centers [1,2]. What that yields is an indication of possible biological and clinical activity alongside limited international validation. Selank holds no FDA drug approval. In the compounding context, the FDA states that information on the safety of human exposure is insufficient and flags possible concerns tied to immunogenicity, aggregation and peptide-related impurities [5].

Proposed Mechanism

No single pathway defines how Selank acts. The GABAergic system is the axis that has drawn the most study: molecular work has suggested the peptide can influence GABA binding and behave as an allosteric modulator at GABA receptors — shifting the receptor’s response rather than simply standing in for GABA itself [3,4]. A second axis involves enkephalins, endogenous peptides that take part in the regulation of pain, stress and emotion. An early report found that Selank inhibits plasma enzymes which degrade enkephalins, and proposed that extending their availability could be part of the explanation for the anxiolytic activity seen in early studies [1]. Gene-expression work in preclinical models likewise shows shifts in neurotransmission-related pathways, though altered gene expression is not in itself proof of clinical improvement. The accurate description is therefore a neuroregulatory peptide with several proposed mechanisms, not a substance with one fully demonstrated mechanism.

The Evidence Base

In one clinical study, 62 patients with generalized anxiety disorder or neurasthenia received either Selank or medazepam. Both groups were reported to improve on anxiety measures, with certain anti-asthenic effects additionally attributed to Selank [2]. A second comparative study set Selank against phenazepam in patients with anxiety and phobic disorders, reporting anxiolytic activity and relatively good tolerability [6]. The caveats are significant: the samples were small, some reports are not available in full in English, the research groups overlap, and no large body of independent multicenter work exists. The depth of this evidence should not be read as equivalent to approved anxiety medications tested in thousands of participants with long-term follow-up. Preclinical data support an effect on GABA and enkephalin systems, but moving from a molecular mechanism to therapeutic benefit calls for larger randomized studies with control groups, predefined outcomes and long-term safety monitoring [1,3,4].

Biological Signal vs. Clinical Outcome in Anxiety and Cognition

Popular discussion sometimes labels Selank a “nootropic,” yet nothing in the literature settles whether healthy people gain wide, repeatable cognitive improvement. Certain studies and models hint at a possible effect on attention, memory or the stress response, but such results depend on the model, the population and the measurement methods used. The distinction that matters most is between a lower anxiety score in a small study and a claim that an anxiety disorder has been treated. Treating a patient means weighing how severe the symptoms are, how daily functioning holds up, whether the condition returns, what other medications are involved, whether paradoxical reactions could occur, and what happens over months and years. On most of those points the existing Selank literature is thin.

Regulatory Status & Safety

Human safety data on Selank remain relatively thin. No severe benzodiazepine-like side-effect profile was described in the small published studies, yet sample sizes of that size leave rare events, long-range effects and interaction with other psychiatric medications unresolved [2,6]. For selank acetate, the FDA states that human information is insufficient to assess safety, and notes that compounded products also carry risks going beyond the peptide’s mechanism: purity of the substance, degradation products, aggregation, immunogenicity and characterization of the active substance [5]. With no uniform regulatory framework in place, the research quality of a given molecule says nothing about the quality of any particular product. That gap is what separates pharmacological research from a medicine that has passed evaluation of quality, stability and manufacturing.

Limits of Interpretation and the Case for Independent Replication

A central limitation in this field is that much of the literature clusters around Russian research groups that were also involved in developing the peptide. That does not invalidate the results, but it does strengthen the case for independent replication and multicenter studies. Establishing a broad clinical role would require studies comparing Selank with placebo and with a standard of care, covering diverse populations, measuring function and quality of life rather than questionnaire scores alone, and tracking side effects over time. Until such work exists, the fairest framing is this: an experimental peptide backed by preliminary human data and intriguing neurobiology, whose evidence base is small next to that of approved treatments.

Bottom Line

Chiefly examined around the GABA and enkephalin systems and the stress response, Selank is a synthetic neuroregulatory peptide [1-4]. A handful of clinical studies have been published, but the evidence stays limited on three counts — sample size, replication beyond its original centers, and long-term follow-up [2,6]. It holds no FDA drug approval, and the safety picture for compounded material is incomplete [5]. The substance is supplied for laboratory research use only.

Selected Research Sources

1. Zozulya A.A. et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 2001. PMID: 11550013
2. Zozulia A.A. et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii, 2008. PMID: 18454096
3. Vyunova T.V. et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein & Peptide Letters, 2018. PMID: 30255741
4. Volkova A.A. et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016. PMID: 26924987
5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Entry for Selank acetate (TP-7), current FDA compounding safety information.
6. Medvedev V.E. et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2014. PMID: 25176261